3 pot stocks to watch in 2018

Although they were quite volatile at times, in the end Australian pot stocks provided investors with some of the best returns on the market last year.

While there’s no guarantee that this will be the case again in 2018, below are three pot stocks which I feel are positioned well to push higher this year:

Auscann Group Holdings Ltd (ASX: AC8)

Although regulations have been loosening in Australia, there’s still a lot of work to do before medicinal cannabis is readily available for sufferers of chronic pain and other ailments. But AusCann is pushing hard for change and if it comes will be well-positioned to profit. Approximately 20% of Australians are believed to suffer from chronic pain, making it an extremely lucrative market for the medicinal cannabis producers.

Botanix Pharmaceuticals Ltd (ASX: BOT)

Botanix is currently conducting a trial of its BTX 1503 candidate which uses synthetic cannabidiol to treat moderate to severe acne. I believe a new treatment for acne is long overdue and that BTX 1503 could win a significant share of the US$4.5 billion acne prescription market if its trials are a success. After all, the current go-to treatment, Accutane, is both expensive and has horrific side effects.

Creso Pharma Ltd (ASX: CPH)

I think that Creso Pharma will be one to watch in 2018 due to the expansion of its business towards the end of last year. This included a move into edibles, China, and the recreational market in Canada. All in all, I think this cashed-up cannabis company could be on the verge of generating material revenues.

Finally, if pot stocks are too risky for you then these exciting tech shares could be better options.

The Disruptors: 3 Revolutionary Aussie Companies to Back for 2018

We’re living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.

That’s why at The Motley Fool we’ve been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Cochlear or REA Group.

We’ve found three exciting companies that we believe re poised to perform in the new year. Click here to uncover these ideas!

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.